
Abbott Presents Positive New Data at TCT on Transcatheter Devices for Tricuspid and Mitral Valve Regurgitation
Abbott has presented new data at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium in San Francisco, demonstrating the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease. The data demonstrates the safety profile and efficacy of its TriClip device and MitraClip device for tricuspid and mitral valve regurgitation respectively.
Mitral and tricuspid valve diseases often result in leaky heart valves, which can significantly reduce the amount of blood pumped through the body, causing the heart to work harder than it should. As a result, these conditions can lead to various cardiovascular problems and severely limit a person’s overall quality of life. Historically, surgical procedures were the primary approach for addressing these conditions.
The first study presented by Abbott was the TRILUMINATE pivotal trial, the world’s first randomized, controlled clinical study evaluating the safety and effectiveness of the TriClip transcatheter edge-to-edge repair (TEER) system for individuals with severe tricuspid regurgitation (TR). The trial compared the TriClip system to optimal medical therapy for patients with symptomatic, severe TR. Key findings of the study included that TriClip therapy significantly improved the patients’ quality of life, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The single-arm group with more complex tricuspid valve anatomies and advanced disease found TriClip to be safe, with 81% of patients achieving a reduction in TR to moderate or less.
The company also presented data from the EXPAND G4 study, a real-world, prospective, multi-center, global study involving over 1,100 patients, highlighting the benefits of the MitraClip G4 system for people with a broad range of mitral valve anatomies. The study demonstrated that MitraClip achieved the highest reported mitral regurgitation (MR) reduction in a transcatheter edge-to-edge repair (TEER) study to date, with 93% of patients reaching MR reduction to mild or less. Significant clinical improvements were observed, with 82% of patients achieving New York Heart Association (NYHA) Functional Class I/II and a 19-point improvement in KCCQ score. MitraClip demonstrated the lowest rates of all-cause mortality (12%) and hospitalization for heart failure (17%) in a global, real-world mitral TEER study.